{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:03:06Z","timestamp":1789556586938,"version":"build-2803163510"},"reference-count":23,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"The study sponsor is ID3 Medical, with funding through a research grant from iVascular"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Endovasc Ther"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>There is evidence that the treatment of symptomatic femoropopliteal disease with a drug-coated balloon (DCB) effectively inhibits restenosis. However for longer and more complex lesions, \u201cbailout\u201d remains stenting almost inevitable. Although the combination therapy of DCBs and modern bare metal stent (BMS) has not been widely studied, there are indications that this combination therapy is doing better than BMS alone and could be a potential alternative for drug-eluting stent treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The aim of this study is to evaluate the long-term outcome of the combination therapy with the Luminor DCB and the iVolution stent of iVascular for the treatment of long femoropopliteal lesions Transatlantic InterSociety Consensus (TASC) C and D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The T.I.N.T.I.N. trial is a physician-initiated, prospective, non-randomized, multicenter trial conducted in Belgium, investigating the safety and efficacy of the treatment with the Luminor DCB and the iVolution self-expanding stent in 100 patients. The primary efficacy endpoint was freedom from clinically-driven target lesion revascularization (CD-TLR) at 12\u2009months. The key secondary endpoints were primary patency at 12\u2009months, CD-TLR at 24\u2009months, and survival at 12 and 24\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Participants had a mean age of 73.5\u2009\u00b1\u20099.4\u2009years, with 67.0% being male participants. Sixty-two percent of the patients suffered from severe claudication (Rutherford 3) and 26.0% had limb-threatening ischemia (Rutherford 5). Freedom from CD-TLR at 12 and 24\u2009months was 94.6% (95% CE: 90.0\u201399.2) and 89.6% (95% CE: 83.2\u201396.0), respectively. The primary patency rate at 12\u2009months was 90.5% (95% CE: 84.2\u201396.8). Survival rate at 1 and 2\u2009years was 92.8% (95% CE: 87.8\u201397.8) and 82.0% (95% CE: 74.2\u201389.8), respectively. None of the causes of death were procedure or device related.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The combination of a Luminor DCB followed by an iVolution stent implantation resulted in safe and effective outcomes in the treatment of femoropopliteal lesions for up to 24\u2009months. Adding paclitaxel to the bare nitinol stent platform by predilating with a Luminor DCB appears to improve efficacy at 1 and 2\u2009years compared to the use of BMSs only, as observed in the precursor Evolution study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Impact<\/jats:title>\n                    <jats:p>This study proofs that especially in long and complex femoropopliteal lesions (full cohort of 100 patients instead of a subanalysis in a small subgroup with risk of biases), a combination therapy of a Paclitaxel coated balloon and a modern bare metal stent offers high levels of safety and efficacy up to 2 years. For clinicians it means that beside bypass surgery, covered self-expandable stents and drug eluting stents, they have an extra treatment option in the armamentarium for complex vascular disease in this anatomic area. Depending on personal preferences, reimbursement systems and device availabilities they can opt for one of these methods.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15266028251350025","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T06:09:33Z","timestamp":1752905373000},"page":"2536-2544","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Efficacy of Treatment With the Luminor DCB and iVolution Stent in TASC C and D Femoropopliteal Atherosclerotic Disease: 12 and 24-Month Outcome of the T.I.N.T.I.N. Physician-Initiated Trial"],"prefix":"10.1177","volume":"33","author":[{"given":"Koen","family":"Deloose","sequence":"first","affiliation":[{"name":"Department of Vascular Surgery, AZ Sint-Blasius, Dendermonde, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Drudi","sequence":"additional","affiliation":[{"name":"Division of Vascular Surgery, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Verbist","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Thoracic surgery, Imelda Hospital, Bonheiden, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2295-8474","authenticated-orcid":false,"given":"Jorn","family":"Robijn","sequence":"additional","affiliation":[{"name":"Department of Vascular and Thoracic surgery, AZ Jan Portaels, Vilvoorde, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"Balduyck","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, AZ Rivierenland, Bornem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Keirse","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, R.Z. Heilig-Hart, Tienen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9890-7097","authenticated-orcid":false,"given":"Peter","family":"Goverde","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, ZNA, Antwerpen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Schepers","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, AZ Damiaan, Oostende, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Dubois","sequence":"additional","affiliation":[{"name":"Department of Vascular and Thoracic Surgery, Heilig Hartziekenhuis, Lier, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2129-0944","authenticated-orcid":false,"given":"Elien","family":"Vernez","sequence":"additional","affiliation":[{"name":"CRO iD3 Medical cvba, Sint-Agatha-Berchem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven","family":"Maene","sequence":"additional","affiliation":[{"name":"Department of Vascular and Thoracic Surgery, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joren","family":"Callaert","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, AZ Sint-Blasius, Dendermonde, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23098"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.10.903"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.25270\/jic\/18.3010.373"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2022.01.290"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.797498"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.109.873703"},{"key":"e_1_3_2_8_2","first-page":"597","article-title":"Paclitaxel eluting balloon: from bench to bedside","volume":"57","author":"Marzullo R","year":"2009","unstructured":"Marzullo R, Aprile A, Clementi F, et al. Paclitaxel eluting balloon: from bench to bedside. Minerva Cardioangiol. 2009; 57:597\u2013609.","journal-title":"Minerva Cardioangiol"},{"key":"e_1_3_2_9_2","first-page":"125","article-title":"Advances on drug-coated balloons","volume":"51","author":"Tepe G","year":"2010","unstructured":"Tepe G, Schmitmeier S, Speck U, et al. Advances on drug-coated balloons. J Cardiovasc Surg (Torino). 2010;51:125\u2013143.","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.09.063"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.11.016"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.026493"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020191619"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602817698634"},{"key":"e_1_3_2_15_2","article-title":"Drug-coated balloon treatment of femoropopliteal lesions for patients with intermittent claudication and ischemic rest pain: 2-year results from the IN.PACT Global Study","volume":"12","author":"Micari A","year":"2019","unstructured":"Micari A, Brodmann M, Keirse K, et al. Drug-coated balloon treatment of femoropopliteal lesions for patients with intermittent claudication and ischemic rest pain: 2-year results from the IN.PACT Global Study. JACC Cardiovasc Interv. 2019;12:e007730.","journal-title":"JACC Cardiovasc Interv"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.04.041"},{"key":"e_1_3_2_17_2","first-page":"6","article-title":"Combining a drug-coated balloon and a bare-metal stent: the REsponse Adapted Combination Therapy (REACT) Strategy Allowing vessel response to guide appropriate treatment for SFA disease","author":"Koen Deloose B","year":"2018","unstructured":"Koen Deloose B, Patrice Mwipatayi B. Combining a drug-coated balloon and a bare-metal stent: the REsponse Adapted Combination Therapy (REACT) Strategy Allowing vessel response to guide appropriate treatment for SFA disease. Suppl Endovasc Today Europe. 2018;6:19\u201323.","journal-title":"Suppl Endovasc Today Europe"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602820952413"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602816656612"},{"issue":"4","key":"e_1_3_2_20_2","first-page":"490","article-title":"Evolution Study : 12 month results","volume":"60","author":"Bosiers M","year":"2019","unstructured":"Bosiers M, Deloose K, Callaert J, et al. Evolution Study : 12 month results. J Cardiovasc Surg (Torino). 2019;60(4):490\u2013495.","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"e_1_3_2_21_2","volume-title":"Presented at LINC 2019","author":"Bosiers M","unstructured":"Bosiers M, Deloose K, Callaert J, et al. Evolution study: 24-month results.Presented at LINC 2019, J Leipzig, Germany."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2013.07.010"},{"key":"e_1_3_2_23_2","first-page":"679","article-title":"Drug coated balloon supported Supera stent versus Supera stent in intermediate and long-segment lesions of the superficial femoral artery: 2-year results of the RAPID Trial","volume":"60","author":"de Boer SW","year":"2019","unstructured":"de Boer SW, de Vries JPPM, Werson DA, et al. Drug coated balloon supported Supera stent versus Supera stent in intermediate and long-segment lesions of the superficial femoral artery: 2-year results of the RAPID Trial. J Cardiovasc Surg. 2019;60:679\u2013685.","journal-title":"J Cardiovasc Surg"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1583\/13-4437MR.1"}],"container-title":["Journal of Endovascular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028251350025","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15266028251350025","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028251350025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:15:09Z","timestamp":1789553709000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15266028251350025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/15266028251350025"],"URL":"https:\/\/doi.org\/10.1177\/15266028251350025","relation":{},"ISSN":["1526-6028","1545-1550"],"issn-type":[{"value":"1526-6028","type":"print"},{"value":"1545-1550","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}